Categories: Articles

Dr. Michelakis May 2012 paper published in Oncogene

Dr. Michelakis May 2012 paper published in Oncogene

 

Oncogene , (21 May 2012) | doi:10.1038/onc.2012.198

Source link: http://www.nature.com/onc/journal/vaop/ncurrent/full/onc2012198a.html

Mitochondrial activation by inhibition of PDKII suppresses HIF1a signaling and angiogenesis in cancer

 

G Sutendra, P Dromparis, A Kinnaird, T H Stenson, A Haromy, J M R Parker, M S McMurtry and E D Michelakis

 

Abstract

Most solid tumors are characterized by a metabolic shift from glucose oxidation to glycolysis, in part due to actively suppressed mitochondrial function, a state that favors resistance to apoptosis. Suppressed mitochondrial function may also contribute to the activation of hypoxia-inducible factor 1α (HIF1α) and angiogenesis. We have previously shown that the inhibitor of pyruvate dehydrogenase kinase (PDK) dichloroacetate (DCA) activates glucose oxidation and induces apoptosis in cancer cells in vitro and in vivo. We hypothesized that DCA will also reverse the ‘pseudohypoxic’ mitochondrial signals that lead to HIF1α activation in cancer, even in the absence of hypoxia and inhibit cancer angiogenesis. We show that inhibition of PDKII inhibits HIF1α in cancer cells using several techniques, including HIF1α luciferase reporter assays. Using pharmacologic and molecular approaches that suppress the prolyl-hydroxylase (PHD)-mediated inhibition of HIF1α, we show that DCA inhibits HIF1α by both a PHD-dependent mechanism (that involves a DCA-induced increase in the production of mitochondria-derived α-ketoglutarate) and a PHD-independent mechanism, involving activation of p53 via mitochondrial-derived H2O2, as well as activation of GSK3β. Effective inhibition of HIF1α is shown by a decrease in the expression of several HIF1α regulated gene products as well as inhibition of angiogenesis in vitro in matrigel assays. More importantly, in rat xenotransplant models of non-small cell lung cancer and breast cancer, we show effective inhibition of angiogenesis and tumor perfusion in vivo, assessed by contrast-enhanced ultrasonography, nuclear imaging techniques and histology. This work suggests that mitochondria-targeting metabolic modulators that increase pyruvate dehydrogenase activity, in addition to the recently described pro-apoptotic and anti-proliferative effects, suppress angiogenesis as well, normalizing the pseudo-hypoxic signals that lead to normoxic HIF1α activation in solid tumors.

suzzy

Share
Published by
suzzy

Recent Posts

DCA Papers and Clinical Trials

DCA papers and clinical trials For almost a decade there has been a growing interest in Dichloroacetate potential to successfully…

2 months ago

DCA History

DCA history Since 1973 Sodium Dichloroacetate (DCA) was used to treat various mitochondrial disorders. It inhibits the activity of pyruvate dehydrogenase kinase,…

2 months ago

Methods and Supplements for Preventing DCA Side Effects

Methods and supplements for preventing DCA side effects When you begin your Sodium dichloroacetate regimen, it is crucial that you take supplementation…

2 months ago

DCA Safety and Side Effects

DCA safety and side effects Sodium dichloroacetate is considered to be a fairly safe alternative cancer treatment. There have been no…

2 months ago

How DCA Works

For almost half a century, DCA has been a relatively basic substance used for treating people with congenital mitochondrial diseases.…

2 months ago

DCA and Cancer: Non-Hodgkin’s lymphoma cured in 4 months (Case presentation)

Today we would like to present you our first article based on Dichloroacetate usage benefits as described in case series.…

2 months ago